Inherited genetics directly shape how our DNA interacts with acquired mutations to drive tumor evolution, according to research published in Nature. Scientists at the University of Cambridge and the University of Edinburgh found that an individual’s genetic background dictates both cancer risk and the specific evolutionary paths tumors take, offering new direction for precision medicine and population-diverse screening strategies.
How Inherited Genetics Dictate Cancer Evolution
Tumors form when cellular DNA accumulates errors that cause rapid growth and override natural cell death signals. While environmental exposures like cigarette smoke or sunlight damage DNA, inherited genetic alterations determine how many mutations accumulate, according to researchers. Although studies long suggested that inherited differences affect cancer risk, proving this link in humans has remained challenging due to varying lifestyles, environments, and exposure histories across populations.
To isolate genetic background from environmental noise, researchers bred four mouse strains with varying susceptibility to liver cancer, matching human population diversity. At 15 days of age, the mice received a single dose of diethylnitrosamine (DEN), a liver carcinogen found in tobacco smoke and processed foods. By controlling exposure timing and dosage, the team eliminated environmental confounding variables. Sequencing nearly 600 tumors revealed how each cancer evolved from its original mutation.
Across all four strains, cancers consistently acquired a driver mutation activating the MAPK signaling system, a molecular cascade controlling cell growth and differentiation. However, depending on the mouse’s inherited genetics, that specific driver mutation altered secondary cancer-associated pathways and triggered widespread whole-genome duplication, where an entire set of chromosomes doubles.
“Cancer does not arise entirely by chance. Although tumors often reach the same biological endpoint, the path to that endpoint is determined by an individual’s genetic background,” said senior author Professor Duncan Odom, who led the research while at the CRUK Cambridge Institute and is now based at the DKFZ (German Cancer Research Centre) in Heidelberg, Germany.
Implications for Cancer Screening and Precision Medicine
The findings indicate that response to DNA-damaging treatments may vary significantly depending on a patient’s background genetics. Because inherited genetics influence both cancer risk and tumor trajectories, future prevention strategies must account for population diversity, according to the study authors.
First author Dr. Sarah Aitken, Assistant Professor at Yale School of Medicine and former researcher at the CRUK Cambridge Institute, noted that diagnostics and treatments may need to adapt. “How people respond to cancer drugs is likely to differ depending on their inherited genetics, and so we may need to tailor our diagnostics and treatments accordingly,” Dr. Aitken said.
Did you know? Most cigarette smokers do not develop lung cancer, while some non-smokers do. Researchers point to inherited genetic makeup as the underlying reason for this divergence in susceptibility under identical environmental exposures.
Dr. Sam Godfrey, research information lead at Cancer Research UK, stated that the study provides a fascinating hint regarding how inherited genes influence cancer development after DNA damage. While further research is needed to fully translate these findings to human patients, the work establishes direct experimental evidence that genetics set the evolutionary trajectory of experimental cancer evolution.
Frequently Asked Questions
What role do inherited genes play in cancer risk?
Inherited genetics interact with acquired mutations to influence how tumors evolve, dictating both overall cancer susceptibility and the specific evolutionary pathways a tumor takes, according to research published in Nature.
Why is it difficult to study inherited cancer risk in humans?
Proving the direct link between inherited genetics and cancer risk in human populations is challenging because individuals vary widely in lifestyle, environment, and exposure history.
How did researchers isolate genetic background from environmental factors?
Scientists controlled environmental factors by breeding four mouse strains with diverse genetics and administering an identical dose of a liver carcinogen at 15 days of age under controlled conditions.
What funding organizations supported this research?
The study was primarily funded by Cancer Research UK, the Medical Research Council, the European Research Council, and Wellcome.
Explore More: Dive deeper into our ongoing coverage of precision medicine and cancer research breakthroughs to stay informed on the latest peer-reviewed findings.
Related reading
- New Research on Exosomes Offers Shingles Pain Treatments
- New Microscope Offers New Hope for IBD Patients
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)